Krazati (adagrasib) — CareFirst (Caremark)
advanced or metastatic colorectal cancer including appendiceal adenocarcinoma and anal adenocarcinoma
Initial criteria
- Tumor or plasma specimen is positive for KRAS G12C mutation
- Requested medication will be used as a single agent or in combination with cetuximab (Erbitux) or panitumumab (Vectibix)
- Member previously received treatment with chemotherapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months